Lorcaserin: A novel antiobesity drug.

J Pharmacol Pharmacother

Department of Pharmacology, Armed Forces Medical College, Pune, Maharashtra, India.

Published: April 2014

Obesity is a major co-morbidity with hypertension and diabetes mellitus. There are few drugs for treatment of obesity like orlistat and recentlty approved drug lorcaserin. Lorcaserin has serotonergic properties and acts as an anorectic. It may cause serious side effects, including serotonin syndrome, particularly when taken with certain medicines that increase serotonin levels or activate serotonin receptors. Although, mainstay and first line of approach of treatment will always remain in having low calorie diet and increase in physical activity. Lorcaserin has come as a new hope to achieve success in treating obese patients but still a long road with further extensive research to be undertaken in the treatment of obesity.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4008925PMC
http://dx.doi.org/10.4103/0976-500X.130158DOI Listing

Publication Analysis

Top Keywords

treatment obesity
8
lorcaserin
4
lorcaserin novel
4
novel antiobesity
4
antiobesity drug
4
drug obesity
4
obesity major
4
major co-morbidity
4
co-morbidity hypertension
4
hypertension diabetes
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!